Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity
In a motion filed Wednesday in the U.S. District Court for the District of Columbia, Hi-Tech says the U.S. Food and Drug Administration must be forced to withhold approval to other generics makers in order to preserve Hi-Tech's exclusivity rights under the Hatch-Waxman Act.
FDA plans to decide...
Already a subscriber? Click here to login